{"groups":[{"description":"Placebo subcutaneous injection (given under the skin by way of a needle) matched to golimumab administered at Week 0 and Week 2. This dosing regimen was selected for the efficacy analysis (only in newly enrolled participants following dose-selection, as per planned analysis).","id":"FG000","title":"Placebo"},{"description":"Golimumab 100 milligram (mg) subcutaneous injection was administered at Week 0 and dose was decreased to 50 mg at Week 2.","id":"FG001","title":"Golimumab 100 mg -> 50 mg"},{"description":"Golimumab 200 mg subcutaneous injection was administered at Week 0 and the dose was decreased to 100 mg at Week 2. This dosing regimen was selected for the efficacy analysis (only in newly enrolled participants following dose-selection, as per planned analysis).","id":"FG002","title":"Golimumab 200 mg -> 100 mg"},{"description":"Golimumab 400 mg subcutaneous injection was administered at Week 0 and the dose was decreased to 200 mg at Week 2. This dosing regimen was selected for the efficacy analysis (only in newly enrolled participants following dose-selection, as per planned analysis).","id":"FG003","title":"Golimumab 400 mg -> 200 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Unsatisfactory therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"331"},{"groupId":"FG001","numSubjects":"72"},{"groupId":"FG002","numSubjects":"331"},{"groupId":"FG003","numSubjects":"331"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"324"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"328"},{"groupId":"FG003","numSubjects":"327"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were assigned to Placebo, Golimumab 100 mg-\\>50 mg, Golimumab 200 mg-\\>100 mg and Golimumab 400 mg-\\>200 mg groups for dose selection. Efficacy results were reported for only newly enrolled participants assigned to Placebo, Golimumab 200 mg-\\>100 mg and Golimumab 400 mg-\\>200 mg groups after dose-selection as per planned analysis."}